Criminal charges prior to and after initiation of office-based buprenorphine treatment

Elizabeth E Harris1, Janet Soeffing Jacapraro2 and Darius A Rastegar3*

Abstract

**Background:** There is little data on the impact of office-based buprenorphine therapy on criminal activity. The goal of this study was to determine the impact of primary care clinic-based buprenorphine maintenance therapy on rates of criminal charges and the factors associated with criminal charges in the 2 years after initiation of treatment.

**Methods:** We collected demographic and outcome data on 252 patients who were given at least one prescription for buprenorphine. We searched a public database of criminal charges and recorded criminal charges prior to and after enrollment. We compared the total number of criminal cases and drug cases 2 years before versus 2 years after initiation of treatment.

**Results:** There was at least one criminal charge made against 38% of the subjects in the 2 years after initiation of treatment; these subjects were more likely to have used heroin, to have injected drugs, to have had any prior criminal charges, and recent criminal charges. There was no significant difference in the number of subjects with any criminal charge or a drug charge before and after initiation of treatment. Likewise, the mean number of all cases and drug cases was not significantly different between the two periods. However, among those who were opioid-negative for 6 or more months in the first year of treatment, there was a significant decline in criminal cases. On multivariable analysis, having recent criminal charges was significantly associated with criminal charges after initiation of treatment (adjusted odds ratio 3.92); subjects who were on opioid maintenance treatment prior to enrollment were significantly less likely to have subsequent criminal charges (adjusted odds ratio 0.52).

**Conclusions:** Among subjects with prior criminal charges, initiation of office-based buprenorphine treatment did not appear to have a significant impact on subsequent criminal charges.

**Keywords:** Opioid-related disorders, Crime, Primary health care, Buprenorphine

Introduction

Substance dependence is a common medical problem and is associated with criminal activity [1,2]. It is estimated that nearly 6 million individuals are arrested each year in the United States and that nearly one half meet criteria for a substance use disorder, but most do not receive treatment [3]. One of the goals of addiction treatment is to reduce criminal activity. A number of studies have reported a decrease in rates of crime when opioid-dependent individuals are enrolled in opioid agonist treatment, both when compared to the period prior to enrollment [4-7], and when compared to those who are not enrolled in opioid agonist treatment [8-10]. However, all of these studies involved subjects who were on methadone maintenance therapy. While office-based buprenorphine treatment has been shown to be an effective treatment for opioid dependence [11], there are no published studies of the effect of office-based buprenorphine maintenance therapy on criminal activity [12].

Given the prevalence of substance use in the criminal justice population [13] and the current limited access to pharmacologic treatment for opioid dependence, there is a tremendous need for effective treatment; incarceration may be an opportunity to initiate treatment for opioid dependence and improve rates of recidivism [14,15]. Buprenorphine maintenance therapy may be more...
acceptable than methadone to criminal offenders released from prison, because of the greater flexibility of receiving prescribed buprenorphine rather than attending a methadone maintenance program on a daily basis [16]. However, subjects with a criminal history may benefit from the more intensive treatment and monitoring that a methadone program offers. Moreover, a criminal history may be associated with poorer treatment retention [17], although one recent study found that a history of incarceration was not associated with poorer outcomes in office-based buprenorphine treatment [18].

The goal of this study is to determine the impact of buprenorphine maintenance therapy in a primary care setting on rates of criminal charges and to examine risk factors for criminal charges in the 2 years after initiation of treatment.

Methods
Setting
The Comprehensive Care Practice is a primary care clinic on the Johns Hopkins Bayview Medical Center campus which is staffed by 5 internists, a nurse practitioner, and 3 internal medicine residents who share a panel of patients. The practitioners provide general primary care, with a focus of serving patients with HIV infection and/or substance use disorders.

Visits for opioid dependence occur as routine primary care visits. A more detailed description of this clinic’s treatment practices has been published previously [19]. Briefly, there is no uniform protocol or dosing regimen, with buprenorphine doses ranging from 2 to 32 mg, with most patients on 8-16 mg daily. Induction occurs at home or in the office and follow-up occurs weekly to monthly, based on the provider’s discretion; patients are usually seen more frequently in early treatment or when there is continued substance use. Treatment is continued or discontinued based on the provider’s discretion. The practice does not provide any additional onsite psychosocial services and patients are referred to community resources.

Subjects
The study included all patients who had received at least one prescription for sublingual formulation of buprenorphine from August 2003 to September 1, 2007.

Data collection
As part of a previously performed study [19], a database of all patients who received at least one prescription for buprenorphine during this period of time had already been created. Data were collected retrospectively from the patient medical records. Demographic information recorded included age, gender, type of insurance and employment status. Substance abuse history collected included substances used and history of injection drug use. We also collected data on recent (within 30 days) drug treatment, including methadone and buprenorphine maintenance. Also recorded were relevant comorbidities (hepatitis C, HIV, chronic pain and chronic psychiatric illness).

The time period after receiving the first prescription was divided into twelve monthly blocks for the purposes of outcomes analysis. Patients were considered to be in treatment for each block in which they were prescribed buprenorphine at any point. There was no fixed protocol for collection of urine drug tests, so for each month in which the patient was receiving treatment, patients were classified as “opioid-positive” or “opioid-negative”. Patients were classified as “opioid-positive” if any of their urine drug tests during that month were positive for opioids (other than those prescribed), if they reported using other non-prescribed opioids, or if a urine drug test was not collected and their most recent test was positive. Patients were classified as “opioid-negative” if all urine drug tests collected during that month were negative for opioids (other than those prescribed), or if the provider decided not to collect a test and their most recent one was negative.

We utilized the Maryland Judiciary Case Search website http://casesearch.courts.state.md.us/inquiry/inquiry-index.jsp to determine whether subjects had any criminal charges and the number of cases filed against each subject. This database includes data on all criminal charges in the state of Maryland since 1991. The database provides the defendant name, city and state, date of birth, trial date, charges, and case disposition. We searched this database by each patient’s name and birthdate, and recorded whether the subject had ever had criminal charges prior to initiating treatment. We tabulated the total number and types of criminal cases two years prior to the date of the first prescription for buprenorphine, and for the two-year period of time after that date. We counted cases as listed separately on the website, not individual charges; we decided to do this because many cases included multiple related charges (for example, multiple charges of drug possession with separate charges for possession of drug paraphernalia). We did not count cases that were limited to motor vehicle charges, with the exception of driving under the influence of alcohol. We classified criminal cases as “drug cases” or “other”; “drug cases” included any cases with charges of possession or distribution of controlled dangerous substances (CDS).

Statistical analysis
Bivariate analysis was used to compare demographic factors and outcomes among subjects with and without criminal charges in the two years after initiation of treatment. We also used bivariate analysis to compare
the mean number of criminal cases in the two years before and after initiation of treatment. We also compared the number of criminal cases before and after initiation of treatment among subjects who remained in treatment at 12 months and those who were opioid negative for 6 or more months. Chi-square tests were used to analyze categorical variables and paired t tests for continuous variables. Wilcoxon signed ranks and Mann Whitney U tests were used to compare variables that were not normally distributed. P values less than 0.05 were considered statistically significant. Multivariate analysis was used to analyze factors associated with criminal charges after initiation of treatment. Variables with a p value < 0.1 were entered into the logistic regression model; for factors that were highly co-linear (Pearson’s correlation coefficient > 0.4), only one was entered. Analysis was performed using PASW software (version 18). This study was approved by the Johns Hopkins Institutional Review Board.

Results

The study included 252 patients who had been given at least one prescription for sublingual formulation of buprenorphine from August 2003 to September 1, 2007. Two subjects from the original cohort were not included because they could not be identified due to gaps in record-keeping.

The number of subjects with at least one criminal charge in the two years after initiating treatment was 97 (38.4%). Table 1 provides demographic and outcome data on subjects with and without criminal charges during this period. A number of characteristics were associated with criminal charges after enrollment in buprenorphine maintenance therapy. Those who reported a history of heroin abuse were more likely to have had criminal charges, while those who reported prescription drug abuse were less likely to have been charged. Hepatitis C virus (HCV) infection and injection drug use (IDU) were also associated with criminal charges. Subjects with criminal charges were less likely to have been receiving opioid maintenance treatment within 30 days prior to initiating treatment at this practice. All of the subjects with criminal charges in the two years after initiating treatment had prior criminal charges, compared to only 67.7% (p < 0.001) of those whom had no criminal charges after initiating treatment; these subjects were also more likely to have had charges in the 2 years prior to initiation of treatment and had a significantly higher median number of prior cases. Subjects with criminal charges in the two years after starting treatment were less likely to achieve ≥ 6 opioid-negative months; they were also less likely to remain in treatment at 12 months, but this difference was not statistically significant.

As shown in Table 2, there was a small decline in the proportion of subjects with at least one criminal charge in the two years before and after initiation of treatment, but this was not statistically significant. Likewise, there was no significant difference in the mean number of criminal cases in the two years before and after enrollment; before enrollment, there was a mean of 0.77 cases per subject, compared to 0.70 cases after enrollment. Among patients who remained in treatment at 12 months, there was no significant difference in the number of criminal cases before and after enrollment. However, among subjects who had ≥ 6 opioid-negative months, there was a significant decline in the mean number of criminal cases.

Similar to the overall charges, there was no significant difference in the proportion of subjects with at least one drug charge. There was also no significant difference in the mean number of drug cases before or after enrollment. Likewise, there was no significant difference in the mean number of drug cases among subjects who remained in treatment at 12 months or among those who achieved ≥ 6 opioid-negative months.

On multivariate analysis, charges in the past 2 years was the strongest predictor of charges in the 2 years after initiation of treatment, as shown in Table 3. Subjects who were receiving opioid maintenance treatment within 30 days of initiating treatment at this practice were less likely to have had subsequent charges. None of the other factors was significantly associated with criminal charges in the two years after initiation of treatment.

Discussion

In this cohort, enrollment in office-based buprenorphine treatment did not seem to result in a significant decline in criminal charges. There likewise was no significant difference in the proportion of subjects who had a drug charge and no significant difference in the mean number of drug cases. However, among the 46% of subjects who were more successful in treatment, defined as ≥ 6 opioid-negative months in the first year after initiation of treatment, there was a significant decline in criminal cases.

This is the first study to our knowledge that looks at the effect of office-based buprenorphine therapy on criminal activity. Initiation of buprenorphine maintenance therapy did not seem to result in a significant decrease in criminal charges, including drug charges. This is in contrast to several studies of subjects in methadone maintenance treatment [4-7]. There are a few possible reasons for these differences. One is that we included all enrollees into our study, not just those who remained in treatment; however, we did not see a significant decline when limiting our analysis to those who remained in treatment at one year. Another
difference is that we used an objective measure rather than self-report. Yet another difference is that subjects in this primary care setting received less intensive monitoring than what is typically provided in methadone maintenance programs. It is possible that these subjects would do better in programs that monitor them closely and provide more psychosocial support.

While treatment retention did not affect rates of criminal charges in our cohort, those who had ≥ 6 opioid-negative months did have a significant decline in criminal charges, suggesting that there was a subgroup in which the treatment was associated with changes in criminal behavior. Other studies have shown that larger reductions in crime are associated with abstinence from opioids. For example, a large study done in England, the National Treatment Outcome Research Study (NTORS), used a national database of convictions and found that there was a significant decline in convictions at 5 years, and that this was associated with reductions in heroin use [20].

Our findings may be relevant to the treatment of recently-incarcerated individuals. Previous studies have shown buprenorphine treatment to be effective in this population and it may be better accepted than methadone maintenance [16]. However, if reduction in criminal activity is a goal, then a referral to office-based buprenorphine treatment alone may not be sufficient. This needs to be studied further and other strategies developed to address the needs of this population.

One factor that may have attenuated the impact of this treatment was that approximately one-fourth of the

| Characteristic                      | Criminal charges (N = 97) | No criminal charges (N = 155) | X², df | P-value\(^a\) |
|-----------------------------------|---------------------------|-------------------------------|--------|--------------|
| Median Age (range)                | 40 (20-56)                | 41 (18-67)                    | 0.770\(^b\) |
| Sex                               |                           |                               |        |              |
| Male                              | 56 (57.7%)                | 86 (55.5%)                    | 0.12, 1| 0.726        |
| Female                            | 41 (42.3%)                | 69 (44.5%)                    |        |              |
| Insurance                         |                           |                               |        |              |
| Commercial                        | 38 (39.2%)                | 66 (42.6%)                    | 0.29, 1| 0.593        |
| Medicaid                          | 36 (37.1%)                | 53 (34.2%)                    | 0.22, 1| 0.637        |
| Medicare                          | 19 (19.6%)                | 23 (14.8%)                    | 0.04, 1| 0.839        |
| None                              | 4 (4.1%)                  | 4 (2.6%)                      | 0.46, 1| 0.497        |
| Employment Status                 |                           |                               |        |              |
| Employed                          | 38 (39.2%)                | 75 (48.4%)                    | 2.07, 1| 0.153        |
| Unemployed                        | 31 (32.0%)                | 43 (27.7%)                    | 0.51, 1| 0.457        |
| Disabled                          | 28 (28.9%)                | 37 (23.9%)                    | 0.78, 1| 0.378        |
| Abused Substances                 |                           |                               |        |              |
| Heroin                            | 90 (92.8%)                | 119 (76.8%)                   | 10.81, 1| 0.001        |
| Opioid Rx                         | 15 (15.5%)                | 57 (36.8%)                    | 13.28, 1| < 0.001     |
| Cocaine                           | 58 (59.8%)                | 76 (49.0%)                    | 0.0033, 1| 0.996       |
| Alcohol                           | 16 (16.5%)                | 26 (16.8%)                    | 2.78, 1| 0.954        |
| Benzodiazepines                   | 8 (8.2%)                  | 15 (9.7%)                     | 0.15, 1| 0.701        |
| Recent opioid maintenance treatment| 18 (18.6%)                | 50 (32.3%)                    | 5.69, 1| 0.017        |
| IDU                               | 67 (69.1%)                | 85 (54.8%)                    | 5.05, 1| 0.025        |
| Co-morbidities                    |                           |                               |        |              |
| HIV                               | 14 (14.4%)                | 22 (14.2%)                    | 0.0033, 1| 0.958       |
| HCV                               | 58 (59.8%)                | 67 (43.2%)                    | 6.55, 1| 0.010        |
| Psychiatric                       | 102 (51.3%)               | 23 (43.4%)                    | 1.60, 1| 0.309        |
| Chronic Pain                      | 35 (17.6%)                | 11 (20.8%)                    | 0.82, 1| 0.596        |
| Any prior criminal charges        | 97 (100%)                 | 105 (67.7%)                   | 39.04, 1| < 0.001     |
| Median number of prior criminal cases (range) | 9 (1-43) | 1 (0-25) | < 0.001\(^b\) |
| Any criminal charges in past 2 years | 62 (63.9%) | 46 (29.7%) | 28.56, 1| < 0.001     |
| ≥ 6 opioid-negative mos.          | 34 (35.1%)                | 83 (53.5%)                    | 2.21, 1| 0.130        |
| 12 mos. in treatment              | 46 (47.4%)                | 93 (60.0%)                    | 3.82, 1| 0.051        |

IDU: injection drug use, HCV: hepatitis C infection, HIV: human immunodeficiency virus infection, df: degrees of freedom

\(^a\) Pearson chi-square test unless otherwise indicated; \(^b\) Mann Whitney U test
subjects had been on opioid maintenance treatment (methadone or buprenorphine) within 30 days of initiating treatment. While those who had recently been on opioid maintenance treatment were less likely to have subsequent criminal charges, when we excluded these subjects from our analysis, we likewise did not find any significant differences in number of criminal cases (total or drug cases) before and after initiation of treatment (data not shown).

A limitation of our study is that we looked only at criminal charges; not all criminal activity leads to criminal charges and not all charges are necessarily indicative of criminal activity (i.e., some may have been wrongly charged). On the other hand, criminal charges are an objective measure and likely correlate with criminal activity. These rates may have been affected by changes in police or criminal justice policies; however, Federal Bureau of Investigation statistics indicate that there has been a decline in crime and arrest rates in Maryland between 2001 and 2009 [21]; therefore, it is unlikely that the absence of a significant decline was due to more aggressive policing or enforcement. Another limitation is that we only looked at criminal charges recorded in Maryland, and could not include crimes committed in other states. However, unlike many other studies, we used an “intention-to-treat” model and included everyone who had received at least one prescription for buprenorphine, not just those who remained in treatment.

In summary, our study suggests that a referral to office-based buprenorphine treatment alone is not sufficient to address criminal behavior among subjects with opioid dependence and a history of criminal charges. It is possible that some of these individuals may benefit from more intensive treatment and monitoring than can be provided in a primary care setting.

Acknowledgements
Preliminary results from this study were presented in abstract form at the 2011 Society of General Internal Medicine national meeting.
Harris et al. Substance Abuse Treatment, Prevention, and Policy 2012, 7:10
http://www.substanceabusepolicy.com/content/7/1/10

Page 6 of 6

Author details
1. Albert Einstein College of Medicine/Montefiore Medical Center, 1621 Eastchester Road Bronx, New York 10461, USA.
2. Health Care for the Homeless, 421 Fallsway, Baltimore, MD 21202, USA.
3. Johns Hopkins School of Medicine, Division of Chemical Dependence, Johns Hopkins Bayview Medical Center, 5200 Eastern Avenue, Baltimore, MD 21224, USA.

Competing interests
The authors declare that they have no competing interests.

Received: 8 December 2011 Accepted: 19 March 2012 Published: 19 March 2012

References
1. Ball JC, Shaffer JW, Nurco DN: The day-to-day criminality of heroin addicts in Baltimore: a study in the continuity of offence rates. Drug Alcohol Depend 1983, 13:119-142.
2. French MT, McGreary KA, Chitwood DD, McCoy CB, Inciardi JA, McBride D: Chronic drug use and crime. Subst Abuse 2000, 21:95-109.
3. Bell JC, Ross A: The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcomes New York: Springer; 1991.
4. Kubiak SP, Artken CL, Swartz JA, Koch AL: Treatment at the front end of the criminal justice continuum: the association between arrest and admission into specialty substance abuse treatment. Subst Abuse Treat Prev Policy 2002, 1:20.
5. Bell J, Mattick R, Hay A, Hall JCW: Methadone maintenance and drug-related crime. J Subst Abuse 1997, 9:15-25.
6. Hubbard RL, Rachal JV, Credico GG, Cavanaugh ER: Treatment Outcome Prospective Study (TOPS): Client characteristics and behaviors before, during, and after treatment. In Drug Abuse Treatment Evaluation: Strategies, Progress, and Prospects. NIDA Research Monograph 51. Edited by: Tims FM, Ludford JP. Rockville: U.S. Department of Health and Human Services; 1984:42-68.
7. Lovernan R, Verhein U: Explaining effectiveness of heroin-assisted treatment on crime reductions. Law Hum Behav 2009, 33:83-95.
8. Dolan KA, Shearer J, White B, Zhou J, Koldor J, Wodak AD: Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005, 100:920-928.
9. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callanan JM, O’Grady KE, Battjes Rj: A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry 2006, 63:102-109.
10. Schwartz RP, Jaffe JH, O’Grady KE, Kinlock TW, Gordon WS, Kelly SM, Wilson ME, Ahmed A: Interim methadone treatment: impact on arrests. Drug Alcohol Depend 2009, 103:148-154.
11. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004, 3:CD002207.
12. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Bullis A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007, 11:1-53.
13. Fazel S, Bains P, Doll H: Substance abuse and dependence in prisoners: a systematic review. Addiction 2006, 101:181-191.
14. Chandler RK, Fletcher BW, Volkow ND: Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009, 30:183-190.
15. Larney S, Tozon B, Dolan K: Effect of prison-based opioid substitution treatment and post-release retention on risk of re-incarceration. Addiction 2011, 107:372-380.
16. Magura S, Lee JD, Hersheiger J, Joseph H, Marsch L, Shropshire C, Rosenblum A: Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depen 2008, 100:148-154.